Clinical Focus

• Cancer> Urologic Oncology
• Bladder Cancer
• Bladder Cancer - Medical Oncology
• Germ Cell Tumors
• Germ Cell Tumors - Medical Oncology

Professional Education

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Current Research Interests

The Genito-Urinary Multidisciplinary tumor board at Stanford specalizes in taking care of patients with prostate cancer, renal cancer, testicular and bladder cancer. Patients are seen at different stages of their tumor. A multisdiscplinary approach is used. A variety of clinical trials are available to patients. Phase II trials using unique combination of chemotherapy agents, antiangiogenic drugs, novel agents are being explored.Co-operative group particpation through ECOG is also available

Clinical Trials

• A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma Recruiting
• Phase I Sodium Selenite in Combination with Docetaxel in Castration-resistant Prostate Cancer Recruiting
• Phase II Pazopanib in Combination with Weekly Paclitaxel in Refractory Urothelial Cancer Recruiting
• Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM) Recruiting
• Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer Recruiting

Publications

• Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P. Clin Cancer Res. 2010; 16 (10): 2906-14
• Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. Harshman LC, Bepler G, Zheng Z, Higgins JP, Allen GI, Srinivas S. BJU Int. 2010
• A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma. Srinivas S, Harshman LC. Chemotherapy. 2009; 55 (5): 321-6
• A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Srinivas S, Feldman D. Anticancer Res. 2009; 29 (9): 3605-10
• Combination therapy with calcitriol and non-steroidal anti-inflammatory drugs in the treatment of prostate cancer Krishnan AV, Srinivas S, Feldman D. Dermato Endocrinolgy. 2009: 1 7-11